



Adjuvants for Human Vaccines

Guest Editors:

Dr. Monzurul Roni

Department of Health Science
Education, College of Medicine,
Peoria Campus, University of
Illinois, Peoria, IL 61605, USA

Dr. Mohammad N. Uddin

College of Pharmacy, Mercer
University, Atlanta, GA 30341,
USA

Deadline for manuscript
submissions:

closed (10 August 2023)

Message from the Guest Editors

The current COVID-19 pandemic has revealed the urgency of vaccines for global health. Vaccines are the most effective method to prevent infectious diseases. In recent decades, mass vaccination has dramatically reduced the incidence of many life-threatening diseases. The vaccine development process involves antigen identification, development and expression, and finally formulation development. There are several ways adjuvants act to enhance the immunogenicity of vaccines. For example, adjuvants act as a depot for the sustained release of the antigen at the site of administration, initiate the up-regulation of cytokines and chemokines, arrange cellular recruitment at the site of injection, increase antigen uptake and presentation to antigen-presenting cells (APC) and/or cause the activation of inflammasomes. This Special Issue focuses on the emerging concepts in the development of adjuvant platforms that have the potential to be safe and to increase vaccine efficiency to protect against current and future infectious threats. Original research, review articles and short communications related to recent advances in adjuvant research for human vaccines will be welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com
[X@Pharmaceut_MDPI](https://twitter.com/Pharmaceut_MDPI)